Saturday 17 October 2026
Export BMEA’s income statement to Excel — free account
Biomea Fusion, Inc.
BMEA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 76.5% and free cash flow grew 47.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.87
0.03
+3.57%
Follow BMEA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Jan '22 | Dec '21 | Jan '21 | Dec '20 | Jan '20 | Dec '19 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
5.23 | 3.15 | 7.84 | 6.17 | 6.17 | 38.08 | 38.08 | 38.43 | 38.43 | — |
Net Debt/EBITDA |
0.68 | 0.41 | 1.42 | 1.37 | 1.37 | 4.24 | 4.26 | 11.60 | 11.88 | 0.00 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.14 | 0.87 | 0.82 | 0.76 | 0.76 | 0.85 | 0.85 | 0.84 | 0.84 | 1.07 |
Capex/Depreciation |
0.00 | (0.21) | (2.22) | (1.23) | 0.00 | (4.15) | 0.00 | (6.37) | 0.00 | — |
| (152.35%) | (125.38%) | (84.42%) | (56.96%) | 0.00% | (45.19%) | 0.00% | (206.84%) | 0.00% | 0.00% | |
| (89.23%) | (98.92%) | (71.23%) | (51.95%) | 0.00% | (33.49%) | 0.00% | (16.96%) | 0.00% | (904.15%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (494.43%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(131.20%) | (274.52%) | (72.61%) | (78.26%) | (76.68%) | (23.77%) | (23.40%) | (8.77%) | (8.74%) | 0.00% |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | — | 0.00% | — | 0.00% | — | — |
Free Cash Flow per Share |
(1.35) | (3.33) | (2.93) | (2.17) | (2.13) | (1.62) | (1.22) | (0.43) | (0.15) | (0.21) |
Cash per Share |
1.07 | 1.61 | 5.19 | 3.86 | 3.86 | 7.27 | 5.96 | 5.86 | 2.05 | 0.00 |
Shareholders Equity per Share |
0.57 | 1.43 | 4.96 | 3.71 | 3.71 | 7.49 | 6.14 | 0.49 | 0.17 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.57 | 1.43 | 4.96 | 3.71 | 3.71 | 7.49 | 6.14 | 0.49 | 0.17 | 0.00 |
Free Cash Flow |
(70.37) | (120.26) | (99.96) | (63.45) | (62.42) | (38.61) | (35.44) | (4.51) | (4.46) | (1.28) |
Working Capital |
46.95 | 46.66 | 156.32 | 98.72 | 98.72 | 171.92 | 171.92 | 60.60 | 60.60 | — |
Capital Expenditures |
— | (0.36) | (3.37) | (1.03) | (1.03) | (3.17) | (3.17) | (0.05) | (0.05) | — |
Net Current Asset Value |
29.03 | 39.97 | 148.49 | 97.05 | 96.52 | 169.64 | 169.02 | 4.87 | 4.87 | 0.00 |
| Other line items | ||||||||||
Quick Ratio |
5.03 | 2.69 | 7.74 | 5.92 | 5.92 | 37.42 | 37.42 | 38.11 | 38.11 | — |
Depreciation/Fixed assets |
9.21 | 0.46 | 0.29 | 0.14 | 0.16 | 0.26 | 0.17 | 0.10 | 0.45 | — |
Cash ROIC |
(82.44%) | (109.47%) | (28.88%) | (28.63%) | (28.17%) | (10.96%) | (10.06%) | (6.75%) | (6.67%) | 0.00% |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | — | 0.00 | — | 0.00 | — | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | — | 0.00 | — | 0.00 | — | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.35) | (3.32) | (2.83) | (2.13) | (2.13) | (1.49) | (1.22) | (0.42) | (0.15) | (0.21) |
Capex per Share |
0.00 | (0.01) | (0.10) | (0.04) | 0.00 | (0.13) | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
8.08 | 9.89 | 6.84 | 4.08 | 4.08 | 1.03 | 1.03 | 0.50 | 0.50 | — |
Average Assets |
69.26 | 139.93 | 164.62 | 157.51 | 157.77 | 124.12 | 124.43 | 31.40 | 31.40 | 0.13 |
Average Common Equity |
40.56 | 110.41 | 138.89 | 143.66 | 143.66 | 91.98 | 91.98 | 2.57 | 2.57 | — |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | — | 0.00 | — | 0.00 | — | — |
Columns are period end dates